Post-chemo olaparib continues to improve efficacy in gBRCApv and high-risk, HER2-negative primary breast cancer
Post-chemo olaparib continues to improve efficacy in gBRCApv and high-risk, HER2-negative primary breast cancer
Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in RR LBCL
Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows favourable efficacy in RR diffuse large B-cell lymphoma
Nivolumab and ipilimumab shows a significantly higher OS rate in nccRCC compared to standard of care
Analysis of dexamethasone-enhanced pre-medication in motixafortide-induced haematopoietic stem cell mobilisation for MM
Bispecific antibody therapy for lymphoma patients failing CAR T-Cell therapy
Teclistamab-based induction regimens demonstrate manageable safety and efficacy in patients with transplant-eligible NDMM
Pembrolizumab shows improvement in overall survival for clear cell renal cell carcinoma
Irradiation plus ADT with GnRH antagonist vs. GnRH agonist shows similar efficacy in high risk locally advanced PC
Demographics, characteristics, survival and outcomes in older, untreated, AML with NPM1 mutations or KMT2A rearrangements
Beat AML master trial update: A clinical trial for acute myeloid leukaemia
Study shows association between tumour KIM-1 gene (HAVCR1) expression and immune infiltrates in RCC